Literature DB >> 21248040

Human cytomegalovirus disrupts the major histocompatibility complex class I peptide-loading complex and inhibits tapasin gene transcription.

Anne Halenius1, Sebastian Hauka, Lars Dölken, Jan Stindt, Henrike Reinhard, Constanze Wiek, Helmut Hanenberg, Ulrich H Koszinowski, Frank Momburg, Hartmut Hengel.   

Abstract

Major histocompatibility complex class I (MHC I) molecules present antigenic peptides for CD8(+) T-cell recognition. Prior to cell surface expression, proper MHC I loading is conducted by the peptide-loading complex (PLC), composed of the MHC I heavy chain (HC) and β(2)-microglobulin (β(2)m), the peptide transporter TAP, and several chaperones, including tapasin. Tapasin connects peptide-receptive MHC I molecules to the PLC, thereby facilitating loading of high-affinity peptides onto MHC I. To cope with CD8(+) T-cell responses, human cytomegalovirus (HCMV) encodes several posttranslational strategies inhibiting peptide transport and MHC I biogenesis which have been studied extensively in transfected cells. Here we analyzed assembly of the PLC in naturally HCMV-infected fibroblasts throughout the protracted replication cycle. MHC I incorporation into the PLC was absent early in HCMV infection. Subsequently, tapasin neosynthesis became strongly reduced, while tapasin steady-state levels diminished only slowly in infected cells, revealing a blocked synthesis rather than degradation. Tapasin mRNA levels were continuously downregulated during infection, while tapasin transcripts remained stable and long-lived. Taking advantage of a novel method by which de novo transcribed RNA is selectively labeled and analyzed, an immediate decline of tapasin transcription was seen, followed by downregulation of TAP2 and TAP1 gene expression. However, upon forced expression of tapasin in HCMV-infected cells, repair of MHC I incorporation into the PLC was relatively inefficient, suggesting an additional level of HCMV interference. The data presented here document a two-pronged coordinated attack on tapasin function by HCMV.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21248040      PMCID: PMC3067861          DOI: 10.1128/JVI.01923-10

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  59 in total

1.  Host immune system gene targeting by a viral miRNA.

Authors:  Noam Stern-Ginossar; Naama Elefant; Albert Zimmermann; Dana G Wolf; Nivin Saleh; Moshe Biton; Elad Horwitz; Zafnat Prokocimer; Mark Prichard; Gabriele Hahn; Debra Goldman-Wohl; Caryn Greenfield; Simcha Yagel; Hartmut Hengel; Yael Altuvia; Hanah Margalit; Ofer Mandelboim
Journal:  Science       Date:  2007-07-20       Impact factor: 47.728

2.  The mechanism of action of tapasin in the peptide exchange on MHC class I molecules determined from kinetics simulation studies.

Authors:  Clemens Schneeweiss; Malgorzata Garstka; James Smith; Marc-Thorsten Hütt; Sebastian Springer
Journal:  Mol Immunol       Date:  2009-04-11       Impact factor: 4.407

3.  High-resolution gene expression profiling for simultaneous kinetic parameter analysis of RNA synthesis and decay.

Authors:  Lars Dölken; Zsolt Ruzsics; Bernd Rädle; Caroline C Friedel; Ralf Zimmer; Jörg Mages; Reinhard Hoffmann; Paul Dickinson; Thorsten Forster; Peter Ghazal; Ulrich H Koszinowski
Journal:  RNA       Date:  2008-07-24       Impact factor: 4.942

4.  The redox activity of ERp57 is not essential for its functions in MHC class I peptide loading.

Authors:  David R Peaper; Peter Cresswell
Journal:  Proc Natl Acad Sci U S A       Date:  2008-07-23       Impact factor: 11.205

5.  Expansion of CD94/NKG2C+ NK cells in response to human cytomegalovirus-infected fibroblasts.

Authors:  Mónica Gumá; Matthias Budt; Andrea Sáez; Tamara Brckalo; Hartmut Hengel; Ana Angulo; Miguel López-Botet
Journal:  Blood       Date:  2005-12-29       Impact factor: 22.113

6.  PRDM1/BLIMP-1 modulates IFN-gamma-dependent control of the MHC class I antigen-processing and peptide-loading pathway.

Authors:  Gina M Doody; Sophie Stephenson; Charles McManamy; Reuben M Tooze
Journal:  J Immunol       Date:  2007-12-01       Impact factor: 5.422

7.  Proteasome-dependent, ubiquitin-independent degradation of Daxx by the viral pp71 protein in human cytomegalovirus-infected cells.

Authors:  Jiwon Hwang; Robert F Kalejta
Journal:  Virology       Date:  2007-06-27       Impact factor: 3.616

8.  Human cytomegalovirus interferes with signal transducer and activator of transcription (STAT) 2 protein stability and tyrosine phosphorylation.

Authors:  Vu Thuy Khanh Le; Mirko Trilling; Manuel Wilborn; Hartmut Hengel; Albert Zimmermann
Journal:  J Gen Virol       Date:  2008-10       Impact factor: 3.891

9.  The comparative roles of suppressor of cytokine signaling-1 and -3 in the inhibition and desensitization of cytokine signaling.

Authors:  Samuel Wormald; Jian-Guo Zhang; Danielle L Krebs; Lisa A Mielke; Jeremy Silver; Warren S Alexander; Terence P Speed; Nicos A Nicola; Douglas J Hilton
Journal:  J Biol Chem       Date:  2006-02-10       Impact factor: 5.157

10.  Selective loading of high-affinity peptides onto major histocompatibility complex class I molecules by the tapasin-ERp57 heterodimer.

Authors:  Pamela A Wearsch; Peter Cresswell
Journal:  Nat Immunol       Date:  2007-07-01       Impact factor: 25.606

View more
  16 in total

1.  Sculpting MHC class II-restricted self and non-self peptidome by the class I Ag-processing machinery and its impact on Th-cell responses.

Authors:  Charles T Spencer; Srdjan M Dragovic; Stephanie B Conant; Jennifer J Gray; Mu Zheng; Parimal Samir; Xinnan Niu; Magdalini Moutaftsi; Luc Van Kaer; Alessandro Sette; Andrew J Link; Sebastian Joyce
Journal:  Eur J Immunol       Date:  2013-03-05       Impact factor: 5.532

2.  Immune regulation and evasion of Mammalian host cell immunity during viral infection.

Authors:  B M Pratheek; Soham Saha; Prasanta K Maiti; Soma Chattopadhyay; Subhasis Chattopadhyay
Journal:  Indian J Virol       Date:  2013-03-15

3.  Impact of beta 2-microglobulin on tapasin expression and covalent association.

Authors:  Laura C Simone; Brittney L Smith; Joyce C Solheim
Journal:  Cell Immunol       Date:  2012-10-01       Impact factor: 4.868

Review 4.  HLA-E: a novel player for histocompatibility.

Authors:  Thomas Kraemer; Rainer Blasczyk; Christina Bade-Doeding
Journal:  J Immunol Res       Date:  2014-10-20       Impact factor: 4.818

Review 5.  Classical and non-classical MHC I molecule manipulation by human cytomegalovirus: so many targets—but how many arrows in the quiver?

Authors:  Anne Halenius; Carolin Gerke; Hartmut Hengel
Journal:  Cell Mol Immunol       Date:  2014-11-24       Impact factor: 11.530

6.  A highly conserved sequence of the viral TAP inhibitor ICP47 is required for freezing of the peptide transport cycle.

Authors:  Tony Matschulla; Richard Berry; Carolin Gerke; Marius Döring; Julia Busch; Jennifer Paijo; Ulrich Kalinke; Frank Momburg; Hartmut Hengel; Anne Halenius
Journal:  Sci Rep       Date:  2017-06-07       Impact factor: 4.379

7.  Human cytomegalovirus Fcγ binding proteins gp34 and gp68 antagonize Fcγ receptors I, II and III.

Authors:  Eugenia Corrales-Aguilar; Mirko Trilling; Katja Hunold; Manuela Fiedler; Vu Thuy Khanh Le; Henrike Reinhard; Katrin Ehrhardt; Eva Mercé-Maldonado; Enver Aliyev; Albert Zimmermann; David C Johnson; Hartmut Hengel
Journal:  PLoS Pathog       Date:  2014-05-15       Impact factor: 6.823

Review 8.  Human cytomegalovirus and autoimmune disease.

Authors:  Anne Halenius; Hartmut Hengel
Journal:  Biomed Res Int       Date:  2014-04-29       Impact factor: 3.411

9.  CEACAM1-Mediated Inhibition of Virus Production.

Authors:  Alon Vitenshtein; Yiska Weisblum; Sebastian Hauka; Anne Halenius; Esther Oiknine-Djian; Pinchas Tsukerman; Yoav Bauman; Yotam Bar-On; Noam Stern-Ginossar; Jonatan Enk; Rona Ortenberg; Julie Tai; Gal Markel; Richard S Blumberg; Hartmut Hengel; Stipan Jonjic; Dana G Wolf; Heiko Adler; Robert Kammerer; Ofer Mandelboim
Journal:  Cell Rep       Date:  2016-06-02       Impact factor: 9.423

10.  Presence of donor-encoded centromeric KIR B content increases the risk of infectious mortality in recipients of myeloablative, T-cell deplete, HLA-matched HCT to treat AML.

Authors:  Will P Bultitude; Jennifer Schellekens; Richard M Szydlo; Chloe Anthias; Sarah A Cooley; Jeffrey S Miller; Daniel J Weisdorf; Bronwen E Shaw; Chrissy H Roberts; Christian A Garcia-Sepulveda; Julia Lee; Rachel M Pearce; Marie C Wilson; Michael N Potter; Jenny L Byrne; Nigel H Russell; Stephen MacKinnon; Adrian J Bloor; Amit Patel; I Grant McQuaker; Ram Malladi; Eleni Tholouli; Kim Orchard; Victoria T Potter; J Alejandro Madrigal; Neema P Mayor; Steven G E Marsh
Journal:  Bone Marrow Transplant       Date:  2020-03-13       Impact factor: 5.483

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.